Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HER2-targeted CAR-T cells + trastuzumab
- Development stage
- Unknown
- Lead developer
- National University Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination therapy consists of autologous chimeric antigen receptor (CAR) T-cells engineered to target the Human Epidermal Growth Factor Receptor 2 (HER2) and the monoclonal antibody trastuzumab. Developed by the National University Hospital, Singapore, this regimen is being evaluated for the treatment of HER2-positive advanced solid tumors, including breast and gastric cancers. The CAR-T cells are designed to directly recognize and eliminate HER2-expressing tumor cells, while trastuzumab, which also binds to HER2, may enhance the anti-tumor effect through antibody-dependent cellular cytotoxicity (ADCC) and inhibition of HER2 signaling. The treatment protocol typically involves lymphodepleting chemotherapy with fludarabine and cyclophosphamide prior to CAR-T cell infusion.
- Brand names
- Herceptin
- Other names
- Autologous Chimeric Receptor T Cells + TrastuzumabChimeric receptor T-cells + trastuzumab-National University Hospital, Singapore-breast cancer-gastric cancer-solid tumors
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HER2-targeted CAR-T cells + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HER2-targeted CAR-T cells + trastuzumab.